News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Durata Therapeutics, Inc.  (DRTX) Submits Marketing Authorization Application For Dalbavancin


12/3/2013 9:10:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for dalbavancin seeking approval for the marketing and sale of dalbavancin for the treatment of patients with complicated skin and soft tissue infections (cSSTI) caused by susceptible Gram-positive microorganisms, including Staphylococcus aureus (including methicillin-resistant strains) and Streptococcus pyogenes, as well as certain other streptococcal species. Following the standard EMA review cycle timing, the Company anticipates a decision in 1H2015.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES